These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34853069)

  • 1. Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
    Maze EA; Agit B; Reeves S; Hilton DA; Parkinson DB; Laraba L; Ercolano E; Kurian KM; Hanemann CO; Belshaw RD; Ammoun S
    Cancer Res; 2022 Jan; 82(2):235-247. PubMed ID: 34853069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.
    Bassiri K; Ferluga S; Sharma V; Syed N; Adams CL; Lasonder E; Hanemann CO
    EBioMedicine; 2017 Feb; 16():76-86. PubMed ID: 28126595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
    James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
    Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
    Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
    Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular prion protein (PrP
    Provenzano L; Ryan Y; Hilton DA; Lyons-Rimmer J; Dave F; Maze EA; Adams CL; Rigby-Jones R; Ammoun S; Hanemann CO
    Oncogene; 2017 Nov; 36(44):6132-6142. PubMed ID: 28692055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
    James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
    Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
    Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
    Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.
    Spear SA; Burns SS; Oblinger JL; Ren Y; Pan L; Kinghorn AD; Welling DB; Chang LS
    Otol Neurotol; 2013 Oct; 34(8):1519-27. PubMed ID: 23928514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
    Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
    Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
    Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
    Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.
    Gehlhausen JR; Hawley E; Wahle BM; He Y; Edwards D; Rhodes SD; Lajiness JD; Staser K; Chen S; Yang X; Yuan J; Li X; Jiang L; Smith A; Bessler W; Sandusky G; Stemmer-Rachamimov A; Stuhlmiller TJ; Angus SP; Johnson GL; Nalepa G; Yates CW; Wade Clapp D; Park SJ
    Hum Mol Genet; 2019 Feb; 28(4):572-583. PubMed ID: 30335132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    Laraba L; Hillson L; de Guibert JG; Hewitt A; Jaques MR; Tang TT; Post L; Ercolano E; Rai G; Yang SM; Jagger DJ; Woznica W; Edwards P; Shivane AG; Hanemann CO; Parkinson DB
    Brain; 2023 Apr; 146(4):1697-1713. PubMed ID: 36148553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
    ; Allaway R; Angus SP; Beauchamp RL; Blakeley JO; Bott M; Burns SS; Carlstedt A; Chang LS; Chen X; Clapp DW; Desouza PA; Erdin S; Fernandez-Valle C; Guinney J; Gusella JF; Haggarty SJ; Johnson GL; La Rosa S; Morrison H; Petrilli AM; Plotkin SR; Pratap A; Ramesh V; Sciaky N; Stemmer-Rachamimov A; Stuhlmiller TJ; Talkowski ME; Welling DB; Yates CW; Zawistowski JS; Zhao WN
    PLoS One; 2018; 13(6):e0197350. PubMed ID: 29897904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
    Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
    Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas.
    Gutmann DH; Giordano MJ; Fishback AS; Guha A
    Neurology; 1997 Jul; 49(1):267-70. PubMed ID: 9222206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours.
    Dave F; Herrera K; Lockley A; van de Weijer LL; Henderson S; Sofela AA; Hook L; Adams CL; Ercolano E; Hilton DA; Maze EA; Kurian KM; Ammoun S; Hanemann CO
    Oncogene; 2024 Oct; 43(41):3049-3061. PubMed ID: 39179860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
    Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
    Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
    Waldt N; Scharnetzki D; Kesseler C; Kirches E; Stroscher N; Böhmer FD; Mawrin C
    J Neurol Sci; 2020 Jan; 408():116553. PubMed ID: 31715329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma.
    Benton D; Yee Chow H; Karchugina S; Chernoff J
    PLoS One; 2024; 19(7):e0305121. PubMed ID: 39083549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
    Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
    Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.